Dasatinib Accordpharma Evropská unie - lotyština - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiski līdzekļi - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Enalapril Polpharma 5 mg tabletes Lotyšsko - lotyština - Zāļu valsts aģentūra

enalapril polpharma 5 mg tabletes

zaklady farmaceutyczne polpharma s.a., poland - enalaprila maleāts - tablete - 5 mg

Enalapril Polpharma 10 mg tabletes Lotyšsko - lotyština - Zāļu valsts aģentūra

enalapril polpharma 10 mg tabletes

zaklady farmaceutyczne polpharma s.a., poland - enalaprila maleāts - tablete - 10 mg

Enalapril Polpharma 20 mg tabletes Lotyšsko - lotyština - Zāļu valsts aģentūra

enalapril polpharma 20 mg tabletes

zaklady farmaceutyczne polpharma s.a., poland - enalaprila maleāts - tablete - 20 mg

Ribavirin Teva Pharma B.V. Evropská unie - lotyština - EMA (European Medicines Agency)

ribavirin teva pharma b.v.

teva b.v. - ribavirīns - c hepatīts, hronisks - pretvīrusu līdzekļi sistēmiskai lietošanai - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4. un 5.. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 un 5.

Sunitinib Be Pharma 12,5 mg cietās kapsulas Lotyšsko - lotyština - Zāļu valsts aģentūra

sunitinib be pharma 12,5 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 12,5 mg

Sunitinib Be Pharma 25 mg cietās kapsulas Lotyšsko - lotyština - Zāļu valsts aģentūra

sunitinib be pharma 25 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 25 mg

Sunitinib Be Pharma 37,5 mg cietās kapsulas Lotyšsko - lotyština - Zāļu valsts aģentūra

sunitinib be pharma 37,5 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 37,5 mg

Sunitinib Be Pharma 50 mg cietās kapsulas Lotyšsko - lotyština - Zāļu valsts aģentūra

sunitinib be pharma 50 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 50 mg

Nilodux 20 mg zarnās šķīstošās cietās kapsulas Lotyšsko - lotyština - Zāļu valsts aģentūra

nilodux 20 mg zarnās šķīstošās cietās kapsulas

pharmaswiss ceska republika s.r.o., czech republic - duloksetīns - zarnās šķīstošās cietās kapsulas - 20 mg